Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 341 across all filing types
Latest filing 2023-10-24 Regulatory Filings
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Kontinuerlig diagnostisk drift og svært positive tilbakemeldinger fra kunder
Regulatory Filings Classification · 95% confidence The document is a press release dated October 24, 2023, detailing positive operational updates, customer feedback, and service performance (diagnostic turnaround times) for Inify Laboratories. It quotes the CEO and CMO and provides contact information. The final sentence states, "Denne informasjonen er informasjonspliktig etter verdipapirhandelloven § 5 -12" (This information is subject to disclosure under the Securities Trading Act § 5-12). This strongly suggests a mandatory regulatory disclosure, but the content itself is an operational update rather than a specific financial report (like 10-K or IR) or a formal announcement of a specific event (like DIV or CAP). Since it is a general, mandatory disclosure of material operational information that doesn't fit the more specific categories (like ER, CT, or DIRS), the most appropriate general category for mandatory regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS). It is too detailed for a simple Report Publication Announcement (RPA) and is not a formal financial statement.
2023-10-24 Norwegian
Continuous diagnostic operation and very positive feedback from customers
Regulatory Filings Classification · 95% confidence The document is a press release dated October 24, 2023, from Inify Laboratories, providing an update on their continuous diagnostic operations, customer feedback, and service quality (short response times, high-quality reports). It quotes the CEO and CMO, discusses their business model, and concludes with contact information and an 'About Us' section. This content structure—a news-style update on business performance and operational milestones, often released outside of mandatory quarterly filings—is characteristic of a general press release or regulatory announcement. Since it is not a formal financial report (like 10-K or IR), a specific management discussion (MDA), or an earnings release (ER) focusing on quantified results, the most appropriate classification is the general regulatory announcement fallback category, RNS, as it serves as a broad disclosure to the market, especially given the final sentence referencing Norwegian Securities Trading Act disclosure requirements.
2023-10-24 English
Kontinuerlig diagnostikverksamhet och mycket positiv kundrespons
Regulatory Filings Classification · 90% confidence The document is a press release dated October 24, 2023, detailing positive operational updates, customer feedback, short turnaround times for cancer diagnostics, and readiness for large-scale service offering by Inify Laboratories. It is not a formal regulatory filing like a 10-K, an earnings release (ER) which usually contains specific financial figures, or a transcript (CT). It is an announcement providing general business and operational progress information. Since it doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), and it is a general update/news item, the most appropriate classification is the general regulatory announcement/news fallback category, RNS, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is safer for a general operational update press release that might be filed with regulators.
2023-10-24 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport andra kvartalet 2023' (Interim Report for the second quarter of 2023) for Inify Laboratories AB. It contains detailed financial performance data, including income statements, cash flow, balance sheet information, and management commentary on business operations, milestones, and outlook. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q2 2023
2023-08-23 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2023' and contains detailed financial information, including operating results, cash flow, balance sheet data, and management commentary for the specified period. It is a comprehensive report rather than a short announcement or certification, fitting the definition of an Interim/Quarterly Report. Q2 2023
2023-08-23 English
Inify Laboratories - Lyckad laboratorielansering under Q2 med leverans av första prostatacancerdiagnoserna
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport andra kvartalet 2023' (Interim Report for the second quarter of 2023) for Inify Laboratories AB. It contains detailed financial performance data, including income statements, cash flow, balance sheet items, and management commentary on business development for the specific quarter. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2023
2023-08-23 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.